Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States. FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
- REV Dashboard
-
Article
Revain (REV) Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara
Cryptocurrency Profile